| Pharmacologic evidence to support clinical decision making for peripartum methadone treatment. | |
| | |
MedLine Citation:
|
PMID: 22926004 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
RATIONALE: Limited pharmacological data are available to guide methadone treatment during pregnancy and postpartum. OBJECTIVES: Study goals were to (1) characterize changes in methadone dose across childbearing, (2) determine enantiomer-specific methadone withdrawal kinetics from steady state during late pregnancy, (3) assess enantiomer-specific changes in methadone level/dose (L/D) ratios across childbearing, and (4) explore relationships between CYP2B6, CYP2C19, and CYP3A4 single-nucleotide polymorphisms and maternal dose, plasma concentration, and L/D. METHODS: Methadone dose changes and timed plasma samples were obtained for women on methadone (n = 25) followed prospectively from third trimester of pregnancy to 3 months postpartum. RESULTS: Participants were primarily white, Medicaid insured, and multiparous. All women increased their dose from first to end of second trimester (mean peak increase = 23 mg/day); 71 % of women increased from second trimester to delivery (mean peak increase = 19 mg/day). Half took a higher dose 3 months postpartum than at delivery despite significantly larger clearance during late pregnancy. Third trimester enantiomer-specific methadone half-lives (range R-methadone 14.7-24.9 h; S-methadone, 8.02-18.9 h) were about half of those reported in non-pregnant populations. In three women with weekly 24-h methadone levels after delivery, L/D increased within 1-2 weeks after delivery. Women with the CYP2B6 Q172 variant GT genotype have consistently higher L/D values for S-methadone across both pregnancy and postpartum. CONCLUSIONS: Most women require increases in methadone dose across pregnancy. Given the shorter half-life and larger clearances during pregnancy, many pregnant women may benefit from split methadone dosing. L/D increases quickly after delivery and doses should be lowered rapidly after delivery. |
| | |
Authors:
|
D L Bogen; J M Perel; J C Helsel; B H Hanusa; M Romkes; T Nukui; C R Friedman; K L Wisner |
Related Documents
:
|
3344944 - The oesophageal detector device. assessment of a new method to distinguish oesophageal ... 7777014 - A pregnancy-prevention program in women of childbearing age receiving isotretinoin. 19168394 - Contraception in historical and global perspective. 6095664 - A comparative trial of the today contraceptive sponge and diaphragm. 16113554 - Effects on the maternofetal unit of the rabbit model after substitution of the amniotic... 15748054 - Plasmodium falciparum infection during pregnancy in an unstable transmission area in ea... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-8-25 |
Journal Detail:
|
Title: Psychopharmacology Volume: - ISSN: 1432-2072 ISO Abbreviation: Psychopharmacology (Berl.) Publication Date: 2012 Aug |
Date Detail:
|
Created Date: 2012-8-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7608025 Medline TA: Psychopharmacology (Berl) Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Pediatrics, Division of General Academic Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, 3414 Fifth Ave, CHOB 3rd floor, Pittsburgh, PA, 15213, USA, bogendl@upmc.edu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination...
Next Document: Sex differences in behavioral and neural cross-sensitization and escalated cocaine taking as a resul...